Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

[1]  Robert Cook-Deegan,et al.  Disclosure of APOE genotype for risk of Alzheimer's disease. , 2009, The New England journal of medicine.

[2]  Anders M. Dale,et al.  Structural Neuroimaging in the Detection and Prognosis of Pre-Clinical and Early AD , 2009, Behavioural neurology.

[3]  L. Kiemeney,et al.  Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.

[4]  P. Bosco,et al.  Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.

[5]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[6]  Magda Tsolaki,et al.  Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study , 2009, The Lancet Neurology.

[7]  P. Aisen,et al.  Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer’s disease: The Alzhemedtm (Tramiprosate) experience , 2009, The journal of nutrition, health & aging.

[8]  E. Siemers.  How can we recognize “disease modification” effects? , 2009, The journal of nutrition, health & aging.

[9]  B. Hyman,et al.  Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575 , 2009, Molecular Neurodegeneration.

[10]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[11]  Stefan J. Teipel,et al.  Decreased Activation Along the Dorsal Visual Pathway After a 3-Month Treatment With Galantamine in Mild Alzheimer Disease: A Functional Magnetic Resonance Imaging Study , 2009, Journal of clinical psychopharmacology.

[12]  Nick C Fox,et al.  Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders , 2009, Current Alzheimer research.

[13]  M. Carrillo,et al.  Early risk assessment for Alzheimer's disease , 2009, Alzheimer's & Dementia.

[14]  A. Fagan,et al.  Alzheimer’s disease risk variants show association with cerebrospinal fluid amyloid beta , 2009, neurogenetics.

[15]  Alison R. Gregro,et al.  First Demonstration of Cerebrospinal Fluid and Plasma Aβ Lowering with Oral Administration of a β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor in Nonhuman Primates , 2009, Journal of Pharmacology and Experimental Therapeutics.

[16]  H. Engler,et al.  PET imaging of amyloid deposition in patients with mild cognitive impairment , 2008, Neurobiology of Aging.

[17]  K. Blennow,et al.  Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial , 2008, The Lancet Neurology.

[18]  A. Fleisher,et al.  Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. , 2008, Archives of neurology.

[19]  C. Masters,et al.  Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial Aβ , 2008, Neuron.

[20]  D. Goldstein,et al.  Global pharmacogenetics: genetic substructure of Eurasian populations and its effect on variants of drug-metabolizing enzymes. , 2008, Pharmacogenomics.

[21]  R. Black,et al.  O3-04-05: Clinical trials of bapineuzumab, a beta-amyloid-targeted immunotherapy in patients with mild to moderate Alzheimer's disease , 2008, Alzheimer's & Dementia.

[22]  K. Blennow,et al.  O3-02-06: Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer's disease , 2008, Alzheimer's & Dementia.

[23]  A. Fagan,et al.  Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition , 2008, Proceedings of the National Academy of Sciences.

[24]  Mark I. McCarthy,et al.  A Genome-Wide Association Study Identifies Protein Quantitative Trait Loci (pQTLs) , 2008, PLoS genetics.

[25]  C. Rowe,et al.  Aβ deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease , 2008, Neuropsychologia.

[26]  K. Blennow,et al.  Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease , 2008, Annals of neurology.

[27]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[28]  C. Jack,et al.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.

[29]  C. Rowe,et al.  Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism , 2008, The Lancet Neurology.

[30]  Stefan J. Teipel,et al.  Novel MRI techniques in the assessment of dementia , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[31]  Janet Woodcock,et al.  The FDA critical path initiative and its influence on new drug development. , 2008, Annual review of medicine.

[32]  Herman Buschke,et al.  Please Scroll down for Article International Review of Psychiatry Mild Cognitive Impairment: Believe It or Not? Mild Cognitive Impairment: Believe It or Not? , 2022 .

[33]  K. Kantarci.  1H magnetic resonance spectroscopy in dementia. , 2007, The British journal of radiology.

[34]  D. Stephan,et al.  A survey of genetic human cortical gene expression , 2007, Nature Genetics.

[35]  R. Tibshirani,et al.  Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.

[36]  Tetsuya Suhara,et al.  Longitudinal, Quantitative Assessment of Amyloid, Neuroinflammation, and Anti-Amyloid Treatment in a Living Mouse Model of Alzheimer's Disease Enabled by Positron Emission Tomography , 2007, The Journal of Neuroscience.

[37]  V. Libri,et al.  PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. , 2007, Brain : a journal of neurology.

[38]  L. Lannfelt,et al.  Reduction of Phosphorylated Tau during Memantine Treatment of Alzheimer’s Disease , 2007, Dementia and Geriatric Cognitive Disorders.

[39]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[40]  Kathryn Ziegler-Graham,et al.  Forecasting the global burden of Alzheimer’s disease , 2007, Alzheimer's & Dementia.

[41]  Josephine Barnes,et al.  Application of automated medial temporal lobe atrophy scale to Alzheimer disease. , 2007, Archives of neurology.

[42]  Mauro Ferrari,et al.  A critical path approach to advance nanoengineered medical products. , 2007, Drug discovery today. Technologies.

[43]  Richard J. Caselli,et al.  Correlations Between Apolipoprotein E ε4 Gene Dose and Whole Brain Atrophy Rates , 2007 .

[44]  K. Blennow,et al.  Longitudinal stability of CSF biomarkers in Alzheimer's disease , 2007, Neuroscience Letters.

[45]  Hilkka Soininen,et al.  CSF Aβ42, Tau and phosphorylated Tau, APOE ɛ4 allele and MCI type in progressive MCI , 2007, Neurobiology of Aging.

[46]  Henrik Zetterberg,et al.  Prediction of Alzheimer’s Disease Using the CSF Aβ42/Aβ40 Ratio in Patients with Mild Cognitive Impairment , 2007, Dementia and Geriatric Cognitive Disorders.

[47]  J. Moffett,et al.  N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiology , 2007, Progress in Neurobiology.

[48]  J. Lirng,et al.  Prediction of Alzheimer's disease in mild cognitive impairment: A prospective study in Taiwan , 2006, Neurobiology of Aging.

[49]  H. Engler,et al.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.

[50]  H. Soininen,et al.  CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. , 2006, Brain : a journal of neurology.

[51]  John A. Wagner,et al.  A cost-effectiveness approach to the qualification and acceptance of biomarkers , 2006, Nature Reviews Drug Discovery.

[52]  Johannes Kornhuber,et al.  Therapeutic approaches to Alzheimer's disease. , 2006, Brain : a journal of neurology.

[53]  K. Blennow,et al.  Neurochemical aftermath of amateur boxing , 2006, Archives of neurology.

[54]  F. Jessen,et al.  Treatment monitoring and response prediction with proton MR spectroscopy in AD , 2006, Neurology.

[55]  F. Jessen,et al.  Multicenter assessment of reliability of cranial MRI , 2006, Neurobiology of Aging.

[56]  Henrik Zetterberg,et al.  Plasma Aβ in Alzheimer's disease—up or down? , 2006, The Lancet Neurology.

[57]  Steven Gutman,et al.  Opinion: The US Food and Drug Administration perspective on cancer biomarker development , 2006, Nature Reviews Cancer.

[58]  Stefan J. Teipel,et al.  Effects of donepezil on cortical metabolic response to activation during 18FDG-PET in Alzheimer’s disease: a double-blind cross-over trial , 2006, Psychopharmacology.

[59]  F. Bouwman,et al.  Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. , 2006, Clinical chemistry.

[60]  B. Reisberg,et al.  Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment , 2006, Neurobiology of Aging.

[61]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[62]  R. Holsinger,et al.  Left insular stroke is associated with adverse cardiac outcome , 2006, Neurology.

[63]  A. Wall,et al.  Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer’s disease , 2006, Journal of Neural Transmission.

[64]  T. Golde,et al.  Anti-Aβ42– and anti-Aβ40–specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model , 2005 .

[65]  J. Morris,et al.  Antecedent Biomarkers of Alzheimer’s Disease: The Adult Children Study , 2005, Journal of geriatric psychiatry and neurology.

[66]  M. Erb,et al.  Cortical activation during cholinesterase-inhibitor treatment in Alzheimer disease: preliminary findings from a pharmaco-fMRI study. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[67]  J. Kaye,et al.  Safety and Acceptability of the Research Lumbar Puncture , 2005, Alzheimer disease and associated disorders.

[68]  C. Jack,et al.  Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2005, Alzheimer's & Dementia.

[69]  Nick C Fox,et al.  Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.

[70]  Ivo D Dinov,et al.  Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. , 2005, Archives of neurology.

[71]  Nick C Fox,et al.  Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease , 2005, Neurology.

[72]  N. Bohnen,et al.  Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer’s disease , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[73]  C. Mirkin,et al.  Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[74]  S. Wagner,et al.  Reductions in β-amyloid concentrations in vivo by the γ-secretase inhibitors BMS-289948 and BMS-299897 , 2005 .

[75]  Anders Wallin,et al.  Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. , 2005, Clinical chemistry.

[76]  B. L. Miller,et al.  Reduced medial temporal lobe N-acetylaspartate in cognitively impaired but nondemented patients , 2005, Neurology.

[77]  K. Ishii,et al.  One-year change in cerebral glucose metabolism in patients with Alzheimer's disease. , 2004, The Journal of neuropsychiatry and clinical neurosciences.

[78]  N. Logothetis,et al.  Neural basis of the blood-oxygen-level-dependent functional magnetic resonance imaging , 2004 .

[79]  C. Masters,et al.  Increased β‐Secretase activity in cerebrospinal fluid of Alzheimer's disease subjects , 2004, Annals of neurology.

[80]  M. Irizarry.  Biomarkers of Alzheimer disease in plasma , 2004, NeuroRX.

[81]  R. Katz,et al.  Biomarkers and surrogate markers: An FDA perspective , 2004, NeuroRX.

[82]  Kaj Blennow,et al.  Cerebrospinal fluid protein biomarkers for Alzheimer’s disease , 2004, NeuroRX.

[83]  T. Lanz,et al.  Studies of Aβ Pharmacodynamics in the Brain, Cerebrospinal Fluid, and Plasma in Young (Plaque-Free) Tg2576 Mice Using the γ-Secretase Inhibitor N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575) , 2004, Journal of Pharmacology and Experimental Therapeutics.

[84]  Juan Manuel Maler,et al.  Neurochemical diagnosis of Alzheimer’s dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau , 2004, Neurobiology of Aging.

[85]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[86]  R. Mani.  The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint , 2004, Statistics in medicine.

[87]  B. Hyman,et al.  Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. , 2003, Neuroimaging clinics of North America.

[88]  K. Blennow,et al.  CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.

[89]  B. Kramer,et al.  A perfect correlate does not a surrogate make , 2003, BMC medical research methodology.

[90]  K. Blennow,et al.  Measurement of α- and β-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients , 2003, Experimental Neurology.

[91]  B. Dubois,et al.  Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization , 2003, Neurology.

[92]  J. Trojanowski,et al.  Biological markers for therapeutic trials in Alzheimer’s disease Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer’s disease , 2003, Neurobiology of Aging.

[93]  R. Hargreaves,et al.  Clinical biomarkers in drug discovery and development , 2003, Nature Reviews Drug Discovery.

[94]  K. Blennow,et al.  CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study , 2003, Neurology.

[95]  A. Convit,et al.  Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment , 2002, Neuroscience Letters.

[96]  N. Logothetis.  The neural basis of the blood-oxygen-level-dependent functional magnetic resonance imaging signal. , 2002, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[97]  G. Alexander,et al.  Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. , 2002, The American journal of psychiatry.

[98]  Nick C Fox,et al.  Mapping the evolution of regional atrophy in Alzheimer's disease: Unbiased analysis of fluid-registered serial MRI , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[99]  S. Younkin,et al.  Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition , 2001, Neurobiology of Aging.

[100]  M S Pepe,et al.  Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.

[101]  F. Chollet,et al.  Within-Session and Between-Session Reproducibility of Cerebral Sensorimotor Activation: A Test–Retest Effect Evidenced with Functional Magnetic Resonance Imaging , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[102]  Kaj Blennow,et al.  Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease , 2001, Neuroscience Letters.

[103]  K. Blennow,et al.  Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke , 2001, Neuroscience Letters.

[104]  H. Hampel,et al.  Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients , 2000, Neuroscience Letters.

[105]  K. Blennow,et al.  Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization , 2000, Neuroscience Letters.

[106]  K. Yanagisawa,et al.  Age-Dependent Change in the Levels of Aβ40 and Aβ42 in Cerebrospinal Fluid from Control Subjects, and a Decrease in the Ratio of Aβ42 to Aβ40 Level in Cerebrospinal Fluid from Alzheimer’s Disease Patients , 2000, European Neurology.

[107]  Nick C Fox,et al.  Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. , 2000, Archives of neurology.

[108]  K. Blennow,et al.  Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma , 2000, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[109]  M. Bobinski,et al.  The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease , 1999, Neuroscience.

[110]  R. Temple,et al.  Are surrogate markers adequate to assess cardiovascular disease drugs? , 1999, JAMA.

[111]  K. Blennow,et al.  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. , 1999, Archives of neurology.

[112]  S. Hirai,et al.  Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in Japan , 1998 .

[113]  S. Hirai,et al.  Combination assay of CSF Tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease , 1998, Journal of the Neurological Sciences.

[114]  M. Mayhaus,et al.  Muscarinic Acetylcholine Receptors Activate Expression of the Egr Gene Family of Transcription Factors* , 1998, The Journal of Biological Chemistry.

[115]  C. Jack,et al.  Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease , 1997, Neurology.

[116]  James R. MacFall,et al.  Accuracy and reproducibility of brain and tissue volumes using a magnetic resonance segmentation method , 1996, Psychiatry Research: Neuroimaging.

[117]  D. DeMets,et al.  Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.

[118]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[119]  A. Smith,et al.  Hippocampal pathology reflects memory deficit and brain imaging measurements in Alzheimer's disease: clinicopathologic correlations using three sets of pathologic diagnostic criteria. , 1996, Dementia.

[120]  N. Risch,et al.  Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease. , 1995, JAMA.

[121]  J. Rapoport,et al.  Reliability of cerebral measures in repeated examinations with magnetic resonance imaging , 1995, Psychiatry Research: Neuroimaging.

[122]  K. Herholz,et al.  Long-term effects of phosphatidylserine, pyritinol, and cognitive training in Alzheimer's disease. A neuropsychological, EEG, and PET investigation. , 1994, Dementia.

[123]  F Fazio,et al.  Comparability of FDG PET studies in probable Alzheimer's disease. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[124]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[125]  K. Herholz,et al.  Effect of Piracetam on Cerebral Glucose Metabolism in Alzheimer's Disease as Measured by Positron Emission Tomography , 1988, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[126]  A. Alavi,et al.  The [18F]Fluorodeoxyglucose Method for the Measurement of Local Cerebral Glucose Utilization in Mane , 1979, Circulation research.

[127]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[128]  Nick C Fox,et al.  Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .

[129]  Harald Hampel,et al.  Decreased activation along the dorsal visual pathway after a 3-month treatment with Galantamine in mild Alzheimer's disease , 2009 .

[130]  A. Verma,et al.  Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study , 2008 .

[131]  K. Blennow,et al.  Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. , 2007, Journal of Alzheimer's disease : JAD.

[132]  M. O. Olde Rikkert,et al.  Current state and future directions of neurochemical biomarkers for Alzheimer's disease. , 2007, Clinical chemistry and laboratory medicine.

[133]  Frederik Barkhof,et al.  Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fMRI study. , 2006, Brain : a journal of neurology.

[134]  K. Blennow,et al.  Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies , 2006, Clinical chemistry and laboratory medicine.

[135]  Yvette I. Sheline,et al.  Potential antecedent marker of Alzheimer disease , 2006 .

[136]  Katharina Buerger,et al.  Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. , 2004, Archives of general psychiatry.

[137]  P. Bossuyt,et al.  BMC Medical Research Methodology , 2002 .

[138]  金井 光康.  Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40, and Aβ1-42(43) in Alzheimer's disease : a study in Japan , 1999 .

[139]  P Leber,et al.  Slowing the progression of Alzheimer disease: methodologic issues. , 1997, Alzheimer disease and associated disorders.

[140]  Levels of (cid:1) -Secretase (BACE1) in Cerebrospinal Fluid as a Predictor of Risk in Mild Cognitive Impairment , 2022 .